That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Diazyme Laboratories, Inc. has acquired Alfa Wassermann Diagnostic Technologies LLC (AWDT) from CARR Biosystems. AWDT, an FDA-registered manufacturer and seller of chemistry systems and reagents based in West Caldwell, New Jersey, will now be integrated into Diazyme’s operations. Dr. Chong Yuan, Managing Director of Diazyme Laboratories, stated that this acquisition enhances Diazyme's customer support network and service excellence. Peter Napoli, CEO of AWDT, noted the synergy between the two companies and their commitment to improving services for customers.
Written locally by qwen2.5:14b on 2026-10-12,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
On October 12, 2026, Diazyme Laboratories, Inc., based in Poway, California, acquired the business of Alfa Wassermann Diagnostic Technologies LLC (AWDT) from CARR Biosystems. Founded in 1960 and headquartered in West Caldwell, New Jersey, AWDT is an FDA-registered manufacturer and seller of chemistry systems and reagents. The acquisition will integrate AWDT’s operations into Diazyme's, enhancing its customer support network across the nation, broadening instrumentation placement, and reinforcing its commitment to service excellence. Dr. Chong Yuan, Managing Director of Diazyme Laboratories, stated that the integration will enable Diazyme to expand access to reliable testing solutions for physicians, veterinarians, researchers, and laboratories. Peter Napoli, CEO of AWDT, noted that joining Diazyme will help provide better services and a wider test menu to customers.
Written for “Diagnostic Technology Acquisition” on 2026-10-13,
grounded in this article and the 0 other(s) covering the same event.
Diazyme Laboratories, Inc. announced today that it has acquired the business of Alfa Wassermann Diagnostic Technologies LLC. (AWDT) from CARR Biosystems.
asserted
it → announce → Biosystems
AWDT is an FDA registered manufacturer and seller of chemistry systems and reagents.
asserted
AWDT → register → systems
Founded in 1960 and headquartered in West Caldwell, New Jersey, AWDT’s business will be integrated into Diazyme’s operations.
asserted
business → found → operations
“Alfa Wassermann Diagnostic Technologies strengthens Diazyme’s ability to serve customers through a strong nationwide customer support network, wide instrumentation placement, and a demonstrated commitment to service excellence,” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories.
asserted
Yuan → strengthen → Laboratories
“Through trusted relationships and highly trained technical-support team, Diazyme will be better positioned to expand access to reliable, accurate testing solutions and support physicians, veterinarians, researchers, and laboratories in making timely, informed decisions.”
asserted
Diazyme → trust → decisions
Mr. Peter Napoli, CEO of Alfa Wassermann Diagnostics Technologies, said joining Diazyme is synergistic for Alfa Wassermann, and will help provide better services and test menu to our customers”.
asserted
joining → say → customers
Mr. Napoli, will continue to manage Alfa Wassermann Diagnostic Technologies business as part of Diazyme’s management team.
asserted
Napoli → continue → team
The Aporia
